# Anti Infective Agent Market

> Anti Infective Agent Market Research Report By Product Type (Antibiotics, Antivirals, Antifungals, Antiparasitics, Others), By Application (Hospital, Clinic, Pharmacy, Home Healthcare, Others), By End User (Individuals, Hospitals, Clinics, Pharmacies, Others) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.82%
- **2024:** $ 59.96 Billion
- **2025:** $ 62.85 Billion
- **2035:** $ 100.66 Billion
- **Key Players:** Pfizer (US), Merck & Co (US), Johnson & Johnson (US), Novartis (CH), GSK (GB), AstraZeneca (GB), Bayer (DE), AbbVie (US), Sanofi (FR)

**Report ID:** MRFR/HC/27129-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/anti-infective-agent-market-28826

---

## Market Summary

## **Anti-infective Agent Market Overview**

As per MRFR analysis, the Anti-infective Agent Market Size was estimated at 59.96 (USD Billion) in 2024. The Anti-infective Agent Market Industry is expected to grow from 62.85 (USD Billion) in 2025 to 96.03 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 4.82% during the forecast period (2025 - 2034).

### **Key Anti-infective Agent Market Trends Highlighted**

The increasing prevalence of infectious diseases and the emergence of antibiotic-resistant strains are driving the growth of the anti-infective agent’s market. The demand for new and innovative treatments is being fueled by the spread of multi-drug-resistant bacteria and the need to combat emerging infectious diseases.

Moreover, the rising awareness of infection prevention and control measures, along with the growing adoption of antimicrobial stewardshipprograms, are contributing to the market growth.****

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Key market drivers include the increasing prevalence of hospital-acquired infections and the rising incidence of antibiotic resistance. Opportunities for growth lie in the development of new and innovative therapeutic approaches, such as targeted therapies and combination therapies.

Recent trends in the market include the increasing focus on precision medicine and the growing adoption of personalized treatment strategies.

## **Anti-infective Agent Market Drivers**

### Increasing Prevalence of Infectious Diseases

The rising incidence of infectious diseases, including bacterial, viral, and fungal infections, is a primary driver of growth in the Anti-infective Agent Market.

Factors such as the emergence of antibiotic-resistant bacteria, increased global travel, and the spread of infectious diseases through contaminated food and water contribute to this trend.

The increasing prevalence of chronic diseases, such as HIV/AIDS and cancer, which weaken the immune system and make individuals more susceptible to infections, further fuels market growth.

### Growing Demand for Advanced Anti-Infective Therapies

The development of new and more effective anti-infective agents is another key driver of market growth. Pharmaceutical companies are investing heavily in research and development to create novel therapies that can combat resistant infections and provide better patient outcomes.

The increasing demand for targeted therapies, personalized medicine, and combination therapies to enhance efficacy and reduce side effects is driving the market.

Technological Advancements and Personalized Medicine

Technological advancements, such as advancements in genomics and molecular diagnostics, are revolutionizing the Anti-infective Agent Market.

These advancements enable the identification of specific pathogens, tailoring therapies to individual patient profiles, and monitoring treatment responses more effectively.

The development of rapid diagnostic tests, point-of-care devices, and personalized treatment approaches are contributing to the growth of the market.

## **Anti-infective Agent Market Segment Insights**

### **Anti-infective Agent Market Product Type Insights**

The Anti-infective Agent Market is segmented by Product Type into Antibiotics, Antivirals, Antifungals, Antiparasitics, and Others. Among these segments, Antibiotics held the largest market share in 2023 and is expected to continue its dominance throughout the forecast period.

The growth of this segment can be attributed to the increasing prevalence of bacterial infections and the rising demand for antibiotics to treat these infections. Antivirals are expected to witness significant growth over the forecast period, owing to the rising incidence of viral infections such as influenza, HIV, and hepatitis.

Antifungals are also expected to experience steady growth, driven by the increasing prevalence of fungal infections, particularly among immunocompromised individuals. Antiparasitics are expected to account for a relatively smaller share of the Anti-infective Agent Market, but they are expected to grow at a steady pace, driven by the rising prevalence of parasitic infections in developing countries.

The Others segment includes a variety of anti-infective agents, such as antitubercular drugs and antiprotozoal drugs. This segment is expected to grow at a moderate pace over the forecast period.

Overall, the Anti-infective Agent Market is expected to exhibit steady growth over the forecast period, driven by the increasing prevalence of infections and the rising demand for effective anti-infective agents.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Anti-infective Agent Market Application Insights**

The application segment of the Anti-infective Agent Market plays a crucial role in shaping the market landscape. Hospitals dominate the market, accounting for a significant share of the revenue due to the high volume of patients seeking treatment for infectious diseases and the availability of advanced medical facilities.

Clinics, with their convenient locations and accessibility, cater to a substantial portion of the market, particularly for minor infections and routine check-ups. Pharmacies serve as essential distribution channels for anti-infective agents, offering both prescription and over-the-counter medications, contributing to a notable share of the market revenue.

Home healthcare, driven by the growing demand for remote patient monitoring and chronic disease management, is expected to witness significant growth in the coming years. Other applications, including long-term care facilities and veterinary medicine, also contribute to the overall market size.

### **Anti-infective Agent Market End User Insights**

The End User segment of the Anti-infective Agent Market is comprised of various entities that utilize these agents for the treatment and prevention of infectious diseases. Key end users include Individuals: Individuals self-administer anti-infective agents, primarily through over-the-counter purchases for minor infections.

In 2023, the market for anti-infective agents among individuals was valued at USD 12.3 billion, driven by rising awareness of self-care and the increasing prevalence of minor infections. Hospitals: Hospitals are major consumers of anti-infective agents due to the high incidence of infections among hospitalized patients.

In 2023, hospitals accounted for approximately 45% of the Anti-infective Agent Market revenue, with a market value of USD 24.7 billion. This is attributed to the widespread use of antibiotics, antifungals, and antivirals for treating infections acquired in hospital settings.

Clinics: Clinics, including outpatient clinics and specialized clinics, contribute significantly to the demand for anti-infective agents. In 2023, the market value for anti-infective agents in clinics was estimated at USD 10.2 billion. This is driven by the increasing number of clinic visits and the growing prevalence of infectious diseases in ambulatory settings.

Pharmacies: Pharmacies serve as a primary distribution channel for anti-infective agents, both over the counter and prescription-based. In 2023, the pharmacy segment held a market share of approximately 18%, with a market value of USD 9.8 billion.

The growth of online pharmacies and the convenience of home delivery are contributing to the increasing demand for anti-infective agents through pharmacies.

Others: This category includes various end users such as nursing homes, long-term care facilities, and veterinary clinics. The market for anti-infective agents in this segment is expected to grow steadily in the coming years due to the increasing geriatric population and rising pet ownership.

### **Anti-infective Agent Market Regional Insights**

The Anti-infective Agent Market size was valued at USD 50.9 billion in 2023, and it is expected to reach USD 77.37 billion by 2032, witnessing a CAGR of 4.8% from 2025 to 2034. Regionally, North America is expected to hold the largest market share of 38.5% in 2023.

This is attributed to the presence of a large number of pharmaceutical companies, well-established healthcare infrastructure, and high healthcare expenditure in the region. Europe is expected to be the second-largest market, with a market share of 31.2% in 2023.

The increasing prevalence of infectious diseases and the growing demand for effective anti-infective agents are driving the growth of the market in this region.

APAC is expected to be the fastest-growing region, with a CAGR of 5.5% from 2025 to 2034. This growth is attributed to the rising healthcare expenditure, increasing population, and growing awareness of infectious diseases in the region. South America and MEA are expected to witness moderate growth during the forecast period.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Anti-infective Agent Market Key Players and Competitive Insights**

Major players in the Anti-infective Agent Market are continuously looking for opportunities to enhance their market position. The competitive landscape of the Anti-infective Agent Market is expected to remain highly competitive in the coming years.

Leading Anti-infective Agent Market players are focusing on developing new products and expanding their global presence to gain a competitive edge. They are also investing in research and development to launch innovative and effective anti-infective agents.

Partnerships and collaborations between different companies are another key strategy adopted by players to strengthen their position in the Anti-infective Agent Market. Companies are also focusing on strategic acquisitions to expand their product portfolio and enter new markets.

Other strategies employed by Anti-infective Agent Market development include mergers, joint ventures, and licensing agreements. The competitive landscape of the Anti-infective Agent Market is expected to intensify further in the future, with new entrants and existing players vying for market share.

Pfizer, a leading player in the Anti-infective Agent Market, is committed to providing innovative and effective treatments for patients around the world. The company has a strong portfolio of anti-infective agents, including antibiotics, antifungals, and antivirals.

Pfizer is also actively involved in research and development to discover and develop new anti-infective agents. The company has a global presence and is working to make its products accessible to patients in all corners of the world. Pfizer is committed to being a leader in the fight against infectious diseases and is dedicated to providing high-quality, affordable medicines to patients in need.

Merck, a competitor company in the Anti-infective Agent Market, is also a leading player in the pharmaceutical industry. The company has a strong focus on research and development and is dedicated to discovering and developing new and innovative treatments for infectious diseases.

Merck has a broad portfolio of anti-infective agents, including antibiotics, antifungals, and antivirals. The company is also actively involved in partnerships and collaborations to accelerate the development and delivery of new anti-infective agents to patients.

Merck is committed to providing high-quality, affordable medicines to patients around the world, and is working to make its products accessible to all who need them.

### **Key Companies in the Anti-infective Agent Market Include**

- AbbVie Inc.
- GlaxoSmithKline plc
- Sanofi Pasteur
- Merck Co., Inc.
- [**Pfizer Inc.**](https://www.pfizer.com/science/focus-areas/anti-infectives)
- Roche Holding Ltd
- Bayer AG
- Abbott Laboratories
- BristolMyers Squibb Company
- Eli Lilly and Company
- Amgen Inc.
- Novartis International AG
- Johnson Johnson
- AstraZeneca Plc

## Anti Infective Agent Market Industry Developments

- **Q2 2024: Gilead Sciences Announces FDA Approval of Sunlenca® (lenacapavir) for HIV-1 Infection in Heavily Treatment-Experienced People With Multidrug-Resistant HIV** Gilead Sciences received FDA approval for Sunlenca® (lenacapavir), a new long-acting injectable anti-infective agent for the treatment of HIV-1 infection in adults with multidrug-resistant HIV, marking a significant regulatory milestone for the company.
- **Q2 2024: Pfizer Receives European Commission Approval for Zavicefta® (ceftazidime-avibactam) for the Treatment of Hospital-Acquired Pneumonia** Pfizer announced that the European Commission approved Zavicefta® for the treatment of hospital-acquired pneumonia, expanding the label of this anti-infective agent in the European market.
- **Q2 2024: GSK Announces Positive CHMP Opinion for Gepotidacin, a First-in-Class Oral Antibiotic for Uncomplicated Urinary Tract Infections** GSK received a positive opinion from the European Medicines Agency’s CHMP for gepotidacin, a novel oral antibiotic, moving the drug closer to regulatory approval in Europe.
- **Q1 2024: Shionogi’s Fetroja® (cefiderocol) Receives FDA Approval for Expanded Use in Bloodstream Infections** Shionogi announced that the FDA approved an expanded indication for Fetroja® (cefiderocol), allowing its use in treating bloodstream infections caused by Gram-negative bacteria.
- **Q2 2024: Sandoz Completes Acquisition of GSK’s Cephalosporin Antibiotics Business** Sandoz finalized its acquisition of GSK’s cephalosporin antibiotics portfolio, strengthening its position in the global anti-infective agent market.
- **Q1 2024: BioVersys Raises €20 Million in Series C Financing to Advance Novel Anti-Infective Therapies** BioVersys secured €20 million in Series C funding to support the clinical development of its pipeline of novel anti-infective agents targeting multidrug-resistant bacterial infections.
- **Q2 2024: Venatorx Pharmaceuticals Announces FDA Priority Review for Cefepime-Taniborbactam NDA** Venatorx Pharmaceuticals received FDA priority review for its New Drug Application for cefepime-taniborbactam, a new anti-infective agent targeting multidrug-resistant Gram-negative infections.
- **Q1 2024: Entasis Therapeutics Announces BARDA Contract for Development of Sulbactam-Durlobactam** Entasis Therapeutics was awarded a contract by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to support the development of sulbactam-durlobactam, an anti-infective agent for drug-resistant Acinetobacter infections.
- **Q2 2024: Pfizer and BioNTech Announce New Partnership to Develop mRNA-Based Anti-Infective Vaccines** Pfizer and BioNTech entered into a partnership to co-develop mRNA-based vaccines targeting infectious diseases beyond COVID-19, expanding their collaboration in the anti-infective space.
- **Q1 2024: GSK Opens New Antibiotics Manufacturing Facility in Singapore** GSK inaugurated a new manufacturing facility in Singapore dedicated to the production of antibiotics, enhancing its global supply capabilities for anti-infective agents.
- **Q2 2024: Abbott Receives CE Mark for New Rapid Molecular Test for Respiratory Infections** Abbott received CE Mark approval for its new rapid molecular diagnostic test for respiratory infections, expanding its portfolio of anti-infective diagnostic solutions in Europe.
- **Q2 2024: F2G Secures $70 Million in Series B Funding to Advance Antifungal Drug Development** F2G raised $70 million in Series B financing to accelerate the development of its novel antifungal agents for the treatment of invasive fungal infections.

## **Anti-infective Agent Market Segmentation Insights**

### **Anti-infective Agent Market Product Type Outlook**

- Antibiotics
- Antivirals
- Antifungals
- Antiparasitics
- Others

### **Anti-infective Agent Market Application Outlook**

- Hospital
- Clinic
- Pharmacy
- Home Healthcare
- Others

### **Anti-infective Agent Market End User Outlook**

- Individuals
- Hospitals
- Clinics
- Pharmacies
- Others

### **Anti-infective Agent Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Rising Incidence of Infectious Diseases

The increasing prevalence of infectious diseases is a primary driver for the Anti-infective Agent Market. As populations grow and urbanization expands, the risk of outbreaks rises, necessitating effective anti-infective agents. According to recent data, the incidence of infectious diseases has surged, with respiratory infections and gastrointestinal diseases leading the charge. This trend compels healthcare systems to invest in anti-infective agents, thereby propelling market growth. The demand for innovative treatments and preventive measures is likely to escalate, as healthcare providers seek to mitigate the impact of these diseases. Consequently, pharmaceutical companies are focusing on developing new anti-infective agents to address this urgent need, indicating a robust market potential.

### Regulatory Support for New Drug Approvals

Regulatory bodies are increasingly providing support for the approval of new anti-infective agents, which is a significant driver for the Anti-infective Agent Market. Initiatives aimed at expediting the review process for novel therapies are encouraging pharmaceutical companies to invest in research and development. For instance, programs that offer fast-track designations and priority review vouchers are incentivizing the development of urgently needed anti-infective agents. This regulatory environment fosters innovation and encourages the introduction of new treatments to the market. As a result, the industry is likely to experience a wave of new products that address unmet medical needs, thereby enhancing market growth.

### Growing Awareness of Antibiotic Stewardship

The increasing awareness surrounding antibiotic stewardship is shaping the Anti-infective Agent Market. Healthcare professionals and organizations are recognizing the importance of responsible antibiotic use to combat resistance. This awareness is driving the demand for alternative anti-infective agents, including those derived from natural sources and novel synthetic compounds. As a result, pharmaceutical companies are investing in research and development to create agents that align with stewardship principles. The market is likely to see a shift towards agents that are effective against resistant strains while minimizing the risk of further resistance development. This evolving landscape indicates a critical need for innovative solutions within the anti-infective sector.

### Rising Investment in Healthcare Infrastructure

The increasing investment in healthcare infrastructure is positively impacting the Anti-infective Agent Market. Governments and private entities are allocating substantial resources to enhance healthcare facilities, particularly in developing regions. This investment is aimed at improving access to essential medicines, including anti-infective agents. As healthcare systems expand and modernize, the demand for effective treatments is expected to rise. Moreover, improved healthcare infrastructure facilitates better disease surveillance and response capabilities, further driving the need for innovative anti-infective solutions. This trend suggests a favorable environment for market growth, as enhanced infrastructure supports the distribution and accessibility of anti-infective agents.

### Technological Advancements in Drug Development

Technological innovations in drug development are significantly influencing the Anti-infective Agent Market. The advent of advanced biotechnological methods, such as CRISPR and high-throughput screening, has streamlined the discovery and development of new anti-infective agents. These technologies enable researchers to identify potential drug candidates more efficiently, reducing the time and cost associated with bringing new treatments to market. Furthermore, the integration of artificial intelligence in drug design is enhancing the precision of targeting pathogens. As a result, the market is witnessing a surge in novel anti-infective agents that are more effective and have fewer side effects. This trend suggests a promising future for the industry, as the pace of innovation continues to accelerate.

## Future Outlook

The Anti-infective Agent Market is projected to grow at a 4.82% CAGR from 2025 to 2035, driven by rising antibiotic resistance, increasing healthcare expenditure, and technological advancements.

**New opportunities:**

- Development of personalized anti-infective therapies
- Expansion of telehealth services for remote consultations
- Investment in AI-driven drug discovery platforms

By 2035, the market is expected to achieve robust growth, reflecting evolving healthcare needs.

## Segment Insights

### By Type: Antibiotics (Largest) vs. Antivirals (Fastest-Growing)

In the Anti-infective Agent Market, antibiotics hold the largest market share due to their widespread use in treating bacterial infections. They dominate this segment as a first line of defense against many infectious diseases, significantly impacting healthcare outcomes. Antivirals, while currently holding a smaller share, are gaining traction rapidly as they respond to the growing prevalence of viral infections, increasing research, and advancements in technology for developing effective antiviral treatments.

Antibiotics (Dominant) vs. Antivirals (Emerging)

Antibiotics are established as the dominant category in the Anti-infective Agent Market, characterized by extensive applications in healthcare systems globally. Their efficacy against bacterial pathogens has made them indispensable in treating infections. However, the segment is evolving with rising concerns about antibiotic resistance necessitating new strategies and innovations. On the other hand, antivirals represent an emerging category, propelled by the increasing incidence of diseases like influenza and COVID-19. This growth is driven by ongoing research into new antiviral agents and therapies, emphasizing the need for effective antiviral solutions in public health, thus making antivirals a focal point for future market developments.

### By Application: Hospital (Largest) vs. Home Healthcare (Fastest-Growing)

In the anti-infective agent market, the distribution of application segments highlights hospitals as the primary setting for usage, holding the largest share. Hospitals have become the central point for the administration of these agents, as they cater to a wide range of infections with a diverse population, housing advanced medical facilities and expertise. Conversely, segments such as clinics, pharmacies, and home healthcare are also significant, yet they generally hold a smaller portion of the market share compared to hospitals.

The growth trends in this segment show an increasing demand for anti-infective agents driven by factors such as the rising prevalence of infectious diseases and a growing aging population. Notably, the home healthcare sector has emerged as the fastest-growing application segment, fueled by shifting patient preferences towards receiving care at home and innovations in telemedicine. This trend indicates a potential resurgence in outpatient treatments, leveraging homecare services as a focal point in managing infections effectively.

Hospital (Dominant) vs. Home Healthcare (Emerging)

In the anti-infective agent market, hospitals play a dominant role as a major application segment, primarily due to their capacity to handle severe infections with specialized treatments. The presence of extensive healthcare resources, advanced diagnostic tools, and inpatient care facilities establishes hospitals as a pivotal hub for administering anti-infective therapies. In contrast, the home healthcare segment is emerging rapidly as an alternative model, appealing to patients desiring the convenience and comfort of receiving treatment at home. This shift is reinforced by technological innovations enabling at-home patient monitoring and telehealth services, making it easier to manage infections without the need for hospital visits. As the healthcare landscape evolves, both segments will continue to shape the future of infection management and treatment.

### By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the Anti-infective Agent Market, the user segment distribution reveals that hospitals predominantly lead the market, accounting for a significant share due to their extensive usage of anti-infectives in managing complex infections. Clinics, while smaller in share compared to hospitals, are witnessing a rapidly increasing demand, particularly in outpatient settings where accessibility to affordable treatments is critical. This growing trend highlights the shifts in healthcare delivery as patients increasingly prefer receiving care in more localized facilities.

The dynamics driving these segments are multifaceted. Hospitals' established infrastructure and robust supply chains enable them to utilize a vast array of anti-infectives effectively. Conversely, clinics are benefitting from the rise of telemedicine and a focus on preventative healthcare, leading to enhanced accessibility and patient engagement. This trend suggests a movement toward decentralized healthcare as patients seek convenient options, further driving the demand for anti-infectives in clinical settings.

Hospitals: Dominant vs. Clinics: Emerging

Hospitals play a dominant role in the Anti-infective Agent Market, characterized by their comprehensive treatment capabilities and extensive patient care facilities. They typically house advanced diagnostic and treatment technologies, which contribute to high prescribing rates of anti-infective agents for serious infections. The focus on infection control in hospitals underscores their primary reliance on these medications to combat hospital-acquired infections effectively. In contrast, clinics represent an emerging segment, growing rapidly as healthcare shifts toward primary care management. They often provide anti-infective treatments that cater to a broad patient demographic, emphasizing affordability and accessibility. This emerging need aligns with healthcare trends favoring prompt treatment of minor infections and preventative care initiatives, positioning clinics as an increasingly vital player in the distribution of anti-infective agents.

## Regional Market Share Analysis

The Anti-infective Agent Market size was valued at USD 50.9 billion in 2023, and it is expected to reach USD 77.37 billion by 2032, witnessing a CAGR of 4.8% from 2025 to 2034. Regionally, North America is expected to hold the largest market share of 38.5% in 2023.

This is attributed to the presence of a large number of pharmaceutical companies, well-established healthcare infrastructure, and high healthcare expenditure in the region. Europe is expected to be the second-largest market, with a market share of 31.2% in 2023.

The increasing prevalence of infectious diseases and the growing demand for effective anti-infective agents are driving the growth of the market in this region.

APAC is expected to be the fastest-growing region, with a CAGR of 5.5% from 2025 to 2034. This growth is attributed to the rising healthcare expenditure, increasing population, and growing awareness of infectious diseases in the region. South America and MEA are expected to witness moderate growth during the forecast period.

## Competitive Benchmarking

Major players in the Anti-infective Agent Market are continuously looking for opportunities to enhance their market position. The competitive landscape of the Anti-infective Agent Market is expected to remain highly competitive in the coming years.Leading Anti-infective Agent Market players are focusing on developing new products and expanding their global presence to gain a competitive edge. They are also investing in research and development to launch innovative and effective anti-infective agents.Partnerships and collaborations between different companies are another key strategy adopted by players to strengthen their position in the Anti-infective Agent Market. Companies are also focusing on strategic acquisitions to expand their product portfolio and enter new markets.Other strategies employed by Anti-infective Agent Market development include mergers, joint ventures, and licensing agreements. The competitive landscape of the Anti-infective Agent Market is expected to intensify further in the future, with new entrants and existing players vying for market share.Pfizer, a leading player in the Anti-infective Agent Market, is committed to providing innovative and effective treatments for patients around the world. The company has a strong portfolio of anti-infective agents, including [antibiotics](https://www.marketresearchfuture.com/reports/antibiotics-market-8447), antifungals, and antivirals.Pfizer is also actively involved in research and development to discover and develop new anti-infective agents. The company has a global presence and is working to make its products accessible to patients in all corners of the world. Pfizer is committed to being a leader in the fight against infectious diseases and is dedicated to providing high-quality, affordable medicines to patients in need.Merck, a competitor company in the Anti-infective Agent Market, is also a leading player in the pharmaceutical industry. The company has a strong focus on research and development and is dedicated to discovering and developing new and innovative treatments for infectious diseases.Merck has a broad portfolio of anti-infective agents, including antibiotics, antifungals, and antivirals. The company is also actively involved in partnerships and collaborations to accelerate the development and delivery of new anti-infective agents to patients.Merck is committed to providing high-quality, affordable medicines to patients around the world, and is working to make its products accessible to all who need them.

## Recent News & Developments

- **Q2 2024: Gilead Sciences Announces FDA Approval of Sunlenca® (lenacapavir) for HIV-1 Infection in Heavily Treatment-Experienced People With Multidrug-Resistant HIV** Gilead Sciences received FDA approval for Sunlenca® (lenacapavir), a new long-acting injectable anti-infective agent for the treatment of HIV-1 infection in adults with multidrug-resistant HIV, marking a significant regulatory milestone for the company.
- **Q2 2024: Pfizer Receives European Commission Approval for Zavicefta® (ceftazidime-avibactam) for the Treatment of Hospital-Acquired Pneumonia** Pfizer announced that the European Commission approved Zavicefta® for the treatment of hospital-acquired pneumonia, expanding the label of this anti-infective agent in the European market.
- **Q2 2024: GSK Announces Positive CHMP Opinion for Gepotidacin, a First-in-Class Oral Antibiotic for Uncomplicated Urinary Tract Infections** GSK received a positive opinion from the European Medicines Agency’s CHMP for gepotidacin, a novel oral antibiotic, moving the drug closer to regulatory approval in Europe.
- **Q1 2024: Shionogi’s Fetroja® (cefiderocol) Receives FDA Approval for Expanded Use in Bloodstream Infections** Shionogi announced that the FDA approved an expanded indication for Fetroja® (cefiderocol), allowing its use in treating bloodstream infections caused by Gram-negative bacteria.
- **Q2 2024: Sandoz Completes Acquisition of GSK’s Cephalosporin Antibiotics Business** Sandoz finalized its acquisition of GSK’s cephalosporin antibiotics portfolio, strengthening its position in the global anti-infective agent market.
- **Q1 2024: BioVersys Raises €20 Million in Series C Financing to Advance Novel Anti-Infective Therapies** BioVersys secured €20 million in Series C funding to support the clinical development of its pipeline of novel anti-infective agents targeting multidrug-resistant bacterial infections.
- **Q2 2024: Venatorx Pharmaceuticals Announces FDA Priority Review for Cefepime-Taniborbactam NDA** Venatorx Pharmaceuticals received FDA priority review for its New Drug Application for cefepime-taniborbactam, a new anti-infective agent targeting multidrug-resistant Gram-negative infections.
- **Q1 2024: Entasis Therapeutics Announces BARDA Contract for Development of Sulbactam-Durlobactam** Entasis Therapeutics was awarded a contract by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to support the development of sulbactam-durlobactam, an anti-infective agent for drug-resistant Acinetobacter infections.
- **Q2 2024: Pfizer and BioNTech Announce New Partnership to Develop mRNA-Based Anti-Infective Vaccines** Pfizer and BioNTech entered into a partnership to co-develop mRNA-based vaccines targeting infectious diseases beyond COVID-19, expanding their collaboration in the anti-infective space.
- **Q1 2024: GSK Opens New Antibiotics Manufacturing Facility in Singapore** GSK inaugurated a new manufacturing facility in Singapore dedicated to the production of antibiotics, enhancing its global supply capabilities for anti-infective agents.
- **Q2 2024: Abbott Receives CE Mark for New Rapid Molecular Test for Respiratory Infections** Abbott received CE Mark approval for its new rapid molecular diagnostic test for respiratory infections, expanding its portfolio of anti-infective diagnostic solutions in Europe.
- **Q2 2024: F2G Secures $70 Million in Series B Funding to Advance Antifungal Drug Development** F2G raised $70 million in Series B financing to accelerate the development of its novel antifungal agents for the treatment of invasive fungal infections.

## Report Scope

| MARKET SIZE 2024 | 59.96(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 62.85(USD Billion) |
| MARKET SIZE 2035 | 100.66(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.82% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Pfizer (US), Merck & Co (US), Johnson & Johnson (US), Novartis (CH), GSK (GB), AstraZeneca (GB), Bayer (DE), AbbVie (US), Sanofi (FR) |
| Segments Covered | Product Type, Application, End User, Regional |
| Key Market Opportunities | Advancements in personalized medicine enhance efficacy in the Anti-infective Agent Market. |
| Key Market Dynamics | Rising antibiotic resistance drives innovation and regulatory scrutiny in the anti-infective agent market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Anti-infective Agent Market as of 2024?**
A: The Anti-infective Agent Market was valued at 59.96 USD Billion in 2024.

**Q: What is the projected market size for the Anti-infective Agent Market in 2035?**
A: The market is projected to reach 100.66 USD Billion by 2035.

**Q: What is the expected CAGR for the Anti-infective Agent Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during 2025 - 2035 is 4.82%.

**Q: Which companies are the key players in the Anti-infective Agent Market?**
A: Key players include Pfizer, Merck & Co, Johnson & Johnson, Novartis, GSK, AstraZeneca, Bayer, AbbVie, and Sanofi.

**Q: What are the main segments of the Anti-infective Agent Market?**
A: The main segments include Antibiotics, Antivirals, Antifungals, Antiparasitics, and Others.

**Q: How much revenue did the Antibiotics segment generate in 2024?**
A: The Antibiotics segment generated revenue between 25.0 and 40.0 USD Billion in 2024.

**Q: What is the revenue range for the Antivirals segment in 2024?**
A: The Antivirals segment had a revenue range of 15.0 to 25.0 USD Billion in 2024.

**Q: What applications are covered in the Anti-infective Agent Market?**
A: Applications include Hospital, Clinic, Pharmacy, Home Healthcare, and Others.

**Q: What is the revenue range for the Hospital application segment in 2024?**
A: The Hospital application segment generated revenue between 20.0 and 32.0 USD Billion in 2024.

**Q: Which end users are involved in the Anti-infective Agent Market?**
A: End users include Individuals, Hospitals, Clinics, Pharmacies, and Others.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/anti-infective-agent-market-28826*